Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2026-02-10 00:00:00 ET · period of report 2026-02-06 · accession 0001601830-26-000014 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-02-10 | 2026-02-06 | RXRX | Khan Najat | CEO, Pres, Dir | A - Grant | $0.00 | +1.70M | 2.28M | +293% | $0 |
| 2026-02-10 | 2026-02-06 | RXRX | Khan Najat | CEO, Pres, Dir | F - Tax | $3.98 | -10.4K | 2.30M | -0.4% | -$41.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-02-06 | A | A | 30,346 | $0.00 | 2,315,027 | D | — | — | |
| 2 | Common | Class A Common Stock | 2026-02-06 | A | A | 1,673,546 | $0.00 | 2,284,681 | D | — | — | |
| 3 | Common | Class A Common Stock | 2026-02-06 | F | D | 10,364 | $3.98 | 2,304,663 | D | — | — |